SITC HCC I/II poster presentation and last patient in
Today, Immunicum announced a poster presentation by Immunicum’s Chief Scientific Officer, Alex Karlsson-Parra, on November 12th, 2016 at the Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting, held in National Harbor, Maryland. The poster – titled “Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers – a phase I/II study in patients with advanced hepatocellular carcinoma” – showed that 67% of fully treated patients with advanced HCC experienced increases in circulating tumor-specific CD8+ T cells.
Moreover, these increases appear to correlate with prolonged survival rates seen in the study as compared to historical median overall survival rates as documented in medical literature. In addition, these results support the achievement of the primary endpoint of the study since INTUVAX demonstrated a positive safety and tolerability profile with only two patients exhibiting treatment related serious adverse events (specifically fever which can be interpreted as a sign of systemic immune responsiveness towards the injected INTUVAX cells).
Read the press release here: (press-release-161114-sitc-poster_lpi)
Read the poster here (immunicum_sitc-poster_2016)